1
Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G Brenner, Daniel J Capon: Human antibodies derived from immunized xenomice. Abgenix, James F Haley Jr, Jane T Gunnison, Fish & Neave, June 13, 2000: US06075181 (548 worldwide citation)

Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipula ...


2
Raju Kucherlapati, Aya Jakobovits, Daniel G Brenner, Daniel J Capon, Sue Klapholz: Human antibodies derived from immunized xenomice. Abgenix, James F Haley Jr, Jane T Gunnison, Fish & Neave, November 21, 2000: US06150584 (441 worldwide citation)

Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed ...


3
Raju Kucherlapati, Aya Jakobovits, Sue Kalpholz, Daniel G Brenner, Daniel J Capon: Generation of xenogeneic antibodies. Abgenix, James F Haley Jr Esq, Jane T Gunnison Esq, Fish & Neave, September 5, 2000: US06114598 (335 worldwide citation)

The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunctio ...


4
Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G Brenner, Daniel J Capon: Generation of Xenogenetic antibodies. Abgenix, James F Haley Jr Esq, Jane T Gunnison Esq, Fish & Neave, December 19, 2000: US06162963 (291 worldwide citation)

The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunctio ...


5
Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G Brenner, Daniel J Capon: Generation of xenogeneic antibodies. Abgenix, James F Haley Jr, Jane T Gunnison, Fish & Neave, January 6, 2004: US06673986 (131 worldwide citation)

The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunctio ...


6
Raju Kucherlapati, Aya Jakobovits, Daniel G Brenner, Daniel J Capon, Sue Klapholz: Human antibodies derived from immunized xenomice. March 30, 2004: US06713610 (75 worldwide citation)

Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed ...


7
Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G Brenner, Daniel J Capon: Human antibodies derived from immunized xenomice. Abgenix, James F Haley Jr, Jane T Gunnison, Fish & Neave, December 2, 2003: US06657103 (51 worldwide citation)

Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipula ...


8
Kenneth L Shepard, Daniel G Brenner: 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines. Merck & Co, Mario A Monaco, William H Nicholson, November 4, 1980: US04232158 (8 worldwide citation)

10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines, derivatives and pharmaceutically acceptable salts thereof are useful as antianxiety agents, as muscle relaxants and in the treatment of extrapyramidal disorders such as in Parkinson's disease. They are prepared by treatment of a 5H-dibenzo[a,d]cy ...


9
Kenneth L Shepard, Daniel G Brenner: Process for the preparation of imino-bridged benzocycloheptapyridines. Merck & Co, Mario A Monaco, William H Nicholson, March 17, 1981: US04256889

Benzocycloheptapyridines with an imine bridge in the cycloheptane ring, derivatives and pharmaceutically acceptable salts thereof are useful as anxiolytics, antidepressants, anticonvulsants, muscle relaxants and in the treatment of mixed anxiety-depression, minimal brain dysfunction and extrapyramid ...


10
Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G Brenner, Daniel J Capon: Generation of xenogeneic antibodies. Abgenix, Fish & Neave, May 13, 2004: US20040093622-A1

The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunctio ...